MBL International provides high-quality products and solutions to advance life science research and clinical diagnostics.

Learn More

Product Highlight

MHC Tetramers


MHC Tetramers and Monomers for high specificity immune monitoring.

Patented α3 mutation for reduced background.

Learn More

Product Highlight

TransFix®: A Cellular Antigen Stabilization Reagent


TransFix® is a versatile cellular antigen stabilization solution that prevents cellular degradation in a variety of specimen types for flow cytometric analysis.

Learn More

Product Highlight

Immuno-Oncology Solutions

MBL International offers Antibodies, MHC Tetramers and Monomers to study immune checkpoint and other cancer research targets.


Learn More

Product Highlight

Autoimmune ANA Test Systems

We offer screens for a wide range of autoantibodies with each lot tested to ensure lot to lot sensitivity.

Learn More
  • Spotlight
  • Promotions
  • Partner
  • Blog
  • News + Events
  • New Products

Novel Neoantigen Screening Tool:  QuickSwitch™ Custom Tetramer Kits

A rapid high throughput and user friendly system for creating new tetramer specificities. Tetramers resulting from peptide exchange with selected peptides can be used for immune monitoring.

Useful for research involving cancer neoantigens, infectious agents and many other research areas.

Learn more about our QuickSwitch™ products.





Partnering with pharmaceutical, biotechnology, and diagnostics companies to out-license our innovative technologies and products supporting life science research, develop companion diagnostics and in-license IVD technologies/products in the areas of cancer, autoimmune diseases, infectious diseases, allergy and cytological/pathological testing.

  • How to detect functional PCSK9 quickly and easily 

    Fri, 30 Mar 2018 18:45:00 GMTBy: (Bindi M. Doshi, PhD)

    PCSK9 remains an important target in cholesterol research.  One of the hurdles in this research area is determining which PSCK9 form is present and binding with LDLR.  Our new Human PCSK9 Functional Assay Kit is designed to detect active PSCK9 binding with LDLR.  Read more
  • Can NanoCulture Plate (NCP) be a better 3D cell culture platform?

    Wed, 28 Mar 2018 17:01:00 GMTBy: mmrahman@MBLINTL.COM (M. Mamunur Rahman, PhD)

    Cell-based assays are the first step for drug screening applications and have been performed in monolayer culture condition for decades. These traditional cell cultures have been known to enhance integrin signals, which mask several biologic activities in tumor cells. In contrast, it is already known that 3D cell culture can replicate the intra-tumor microenvironment.
    Epithelial Mesenchymal Transition (EMT) is a biologic process for carcinoma progression as it is related to cancer invasion or metastasis that remains the primary cause of cancer mortality worldwide. In EMT process, tumor cells dissociate and become motile, leading to localized invasion and metastatic spread. In addition to the morphological changes, key factors/markers in the steps of EMT have been established including cell adhesion molecules and, transcription factors and kinases[i]. During cancer progression, cancer cells assume a spindled shape, lose desmosomes and adherence junctions, and express mesenchymal genes, such as vimentin and zeb-19,[ii]. These EMT markers are correlated with drug resistance[iii] and tumor progressions[iv]. Targeting EMT therefore represents an important therapeutic strategy for cancer treatment. Recently, Kumar et al. reported that mesenchymal transition of non-small cell lung cancer (NSCLC) cell lines were much more efficiently induced on 3D cell culture than that on 2D cell culture[v]. This result persuades us to develop a novel 3D screening system.
    In our recent publication Arai et al.[vi], we have introduced an innovative three-dimensional (3D) cell based high throughput screening assay that can lead to the identification of EMT inhibitors. We have cultured cells on NanoCulture Plate (NCP), a micro-patterned gel free scaffold type 3D cell culture plate, to mimic in vivo tumor micro environment. This ECM mimicking structure on the NCPs restricts cells to sprawl on the base and enable tumor cells to migrate more than monolayer cell culture. Cells can migrate more actively from a scaffold to the other scaffold on the grid in the NCPs than cells on 2D cell culture plate, on which cells migrate less. On the other hand, easy handling, microscopic compatibility, in plate application performance, and SBS format compatibility make NCP better platform than other scaffold based 3D system. Therefore the NanoCulture Plates are useful for scaffold-based type 3D tissue culture system based on micro-patterned surface without gels.
    Lung cancer cell lines have been treated with TGFβ to stimulate the spheroid to induce EMT and observed the extent of EMT by the morphology change under a HTS measurement method using hypoxia probe, in order to quantify more accurate data. This “add only” assay is simplest and suitable for HTS. Further researchers may enable to cross validate their data performing WB/RNA of common EMT biomarkers panel (i.e. Vimentin, Zeb-1, N-cadherin, E-cadherin) at the end as this is a live cell imaging probe. A pilot screen has been conducted to validate this model for HTS using LOPAC and identified several compounds as viable EMT inhibitors. Overall, we hope that this 3D EMT HTS method will provide an immense improvement of therapeutic medicine.
    Fig: EMT on NanoCulture Plate. A549 cells were cultured with or without TGF-β2 only or TGF-β2 + SB431542 for 4 days. Representative images were shown. Scale bar, 200 μm
    [i] Lamouille S, Xu J, & Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. (2014) Nature reviews Molecular cell biology. 15(3): 178-196.
    [ii] Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. (2009) Nat Cell Biol. 11: 1487-95.
    [iii] Pan JJ, Yang MH. (2011) The role of epithelial-mesenchymal transition in pancreatic cancer. J Gastrointest Oncol. 2: 151-6.
    [iv] Liu J, Chen L, Deng H, Xu B, Li M, Zheng X, … & Jiang J. Epithelial-to-mesenchymal transition in human esophageal cancer associates with tumor progression and patient’s survival. (2014) International journal of clinical and experimental pathology. 7(10): 6943.
    [v] Kumar M, Allison DF, Baranova NN, Wamsley JJ, Katz AJ, Bekiranov S, Jones DR, Mayo MW. NF-κB regulates mesenchymal transition for the induction of non-small cell lung cancer initiating cells. (2013) PLoS One. 8: e68597.
    [vi] Arai K, Eguchi T, Rahman MM, Sakamoto R, Masuda N, Natatsura T, Calderwood SK, Kozaki KI, Itoh M.  A Novel High-Throughput 3D Screening System for EMT Inhibitors: A Pilot Screening Discovered the EMT Inhibitory Activity of CDK2 Inhibitor SU9516. (2016) PLoS One. 11(9): e0162394. Read more
  • Quick!  Switch out your peptide! 

    Tue, 27 Mar 2018 16:58:00 GMTBy: Marc.Delcommenne@MBLINTL.COM (Marc Delcommenne, PhD)

    The immunotherapy field is making great progress in aiding many disease treatments.  The hope is that one day, personalized immunotherapy can be used so each patient can use their own immune system to overcome their specific disease affliction.  QuickSwitch is a tool for creating custom MHC class I tetramers quickly and easily. Read more

View All

MBL International will be attending:


Press Release

JSR’s Life Sciences Division Appoints New CEO for MBL International


Jan. 23, 2018 – Sunnyvale, CA – JSR Life Sciences, the life sciences-focused business unit of JSR Corporation, announced today that it has appointed Dr. Nalini Murdter as the President and Chief Executive Officer of MBL International (MBLI) effective immediately.

Read More

May 22nd, 2017: MEDICAL & BIOLOGICAL LABORATORIES Co., Ltd. (MBL) announced that it has entered into a collaboration agreement with the p53 Laboratory, Agency for Science, Technology and Research (A*STAR) in Singapore to establish the novel screening technology which accelerates the drug discovery targeting Protein-Protein Interactions (PPIs).

February 28th, 2017: MEDICAL & BIOLOGICAL LABORATORIES Co., Ltd. concludes a patent licensing agreement with the University of Toyama concerning a rapid antibody production technique



  • p62 ELISA Kits– Complementary products to our p62 antibodies and extensive autophagy antibody portfolio
  • QuickSwitch™ Custom Tetramer Kits – Create new specificity tetramers for antigen-specific t cell detection in just a few hours
  • TransFix® – A patented stabilization solution that is easy to use and preserves cells and cellular antigens for up to 14 days prior to analysis
  • Exosome Storage Booster – Improve the recovery rate of exosomes from cell culture supernatant using ultracentrifugation